NRG-CC004, “Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer,” will close to accrual at 5 PM ET Friday April 24, 2020 due to drug expiration dates. If a patient has been consented and eligibility confirmed please register before the closure date. All patients registered to Step 1 registration by Friday, April 24 will be permitted to proceed to the randomization step (Step 2). All patients randomized to Step 2 must begin treatment by May 11.

Reminder: Data collection and site IRB renewal for closed studies must continue until the study is terminated.

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.